Physician profile
Paul Subrt
NPI 1346252798
$1,549.22
in general payments reported to CMS, 2019-2025
11 companies · $730 in 2025
The $730 reported for 2025 was more than what 84% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30.00 · 2022: $31.39 · 2023: $207 · 2024: $551 · 2025: $730.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,488.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,487.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $624.87 | 2023-2025 | Skyrizi, Rinvoq |
| Arcutis Biotherapeutics, INC. | $377.14 | 2023-2025 | Zoryve |
| Janssen Biotech, INC. | $261.28 | 2022-2025 | Tremfya |
| Amgen INC. | $54.58 | 2024-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $50.13 | 2023-2025 | Sotyktu |
| Genzyme Corporation | $44.36 | 2025 | |
| Ucb, INC. | $43.27 | 2024-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $31.00 | 2025 | |
| Leo Pharma INC. | $30.00 | 2019 | |
| Verrica Pharmaceuticals INC. | $18.08 | 2025 | Ycanth |
| Lilly USA, LLC | $14.51 | 2025 | Ebglyss |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Subrt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.